'Practically clean' FDA user fees reauth will be included in spending bill wrapping up next week
The long and winding road to reauthorizing FDA’s quinquennial user fees for prescription drugs, generics, biosimilars and medical devices finally has a light at the end of it.
While negotiations are still ongoing on which policy riders (accelerated approval reforms, et. al.) may be included, a senior GOP committee aide confirmed to Endpoints News Thursday that at the very least, an agreement has been reached for the FDA user fee deals, which are good through 2027, to be included in the continuing resolution.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.